This issue features articles on the firm’s Business Advisory Practice supporting Nervosave Therapeutics’ U.S. expansion; the USPTO’s forthcoming guidance on AI innovation protection; option pool sizes for life sciences companies; life sciences venture financings for clients in 2H 2022 and 1H 2023; and Congress’s attempts to improve medical diagnostics patent eligibility. It also includes a client interview with SonoThera CEO Kenneth Greenberg, an article on DOJ’s incentives for life sciences companies to self-disclose misconduct, and a Q&A with Ed Shenkan on decreasing risk from medical device concept to commercialization, as well as details on recent life sciences-focused NextGen VC Forums hosted by Wilson Sonsini and LaunchBio, the 28th annual Phoenix Conference and 2023 Life Sciences Investment Forum, and select life sciences client highlights.

Please click here to read the publication.